目的: 采用高分辨LC-PDA-QTOF-MS联用强降解方法对盐酸帕罗西汀片检测过程中的未知峰进行调查,确定该未知杂质的结构及产生的根本原因,制定出该未知峰控制策略。方法: 在LC-MS研究中,目标杂质(RRT 0.55杂质)与主成分帕罗西汀可以完全分离。通过高分辨LC-PDA-QTOF-MS方法确定目标杂质的紫外吸收光谱及一级、二级高分辨质谱数据,并与药物活性成分帕罗西汀进行比较,推测出目标杂质的可能结构,并根据基于目标杂质结构进行的强制降解研究,证明该杂质的产生机理,并提出它的控制措施。结果: 通过LC-PDA-QTOF-MS试验结果,推测目标杂质为药物活性成分帕罗西汀与处方中的乳糖发生Maillard反应产生的杂质,并且通过试验确认,目标杂质在盐酸帕罗西汀片分析溶液制备过程中,配制溶液pH选择不当造成的。通过控制样品制备过程中稀释液的pH,并优化了样品溶液制备过程,此杂质的含量明显下降,并低于最终产品的报告限度(≤0.05%)。结论: 盐酸帕罗西汀片中RRT 0.55未知杂质的产生大部分源于分析方法本身,不是产品中的真实杂质;通过优化分析方法过程中稀释液的pH,可以控制该未知峰的产生,从而准确分析盐酸帕罗西汀片的质量。
周丽萍, 吕倩倩, 郑乐伟, 钟雪妮, 万恒, 李敏, 林金生
. 运用高分辨LC-PDA-QTOF-MS联用强降解研究方法调查盐酸帕罗西汀片中未知杂质峰*[J]. 药物分析杂志, 2022
, 42(9)
: 1608
-1617
.
DOI: 10.16155/j.0254-1793.2022.09.14
Objective: To identify the structure and root cause of the unknown impurity in paroxetine hydrochloride tablet by LC-PDA-QTOF-MS. To prove the mechanism by forced degradation studies. To propose an effective control strategy to control the unknow impurity. Methods: The RRT 0.55 impurity that affected quality of the final product of paroxetine hydrochloride tablets were well separated from the main peak by optimizing the LC-MS chromatography conditions. The structure of RRT 0.55 impurity was confirmed by LC-MS/MS and UV absorption spectra by comparing the differences between those of paroxetine and RRT 0.55 impurity. The fragment peaks and generation pathway were analyzed. Structure of this impurity and the formation mechanism was verified with the structure-based forced studies. Results: The RRT 0.55 impurity was identified as a paroxetine-lactose adduct by LC-PDA-QTOF-MS/MS which was generated by the Maillard reaction between paroxetine with lactose. By optimizing the pH of the diluent in the sample preparation procedure of paroxetine hydrochloride tablets, this impurity was significantly decreased to lower than the reported limit in the final product (≤0.05%). Conclusion: The unknown RRT 0.55 impurity in paroxetine hydrochloride tablets is mainly resulted from the solution degradation in the process of sample preparation and it is not the true impurity in paroxetine hydrochloride tablets. By optimizing the pH of the diluent in the sample preparation procedure of paroxetine hydrochloride tablet, generation of this unknown peak can be controlled, and the true level of this unknown impurity can be determined in the modified method.
[1] KELCE WR, CASTLE KE, NDIKUM-MOFFOR FM, et al. Drug substance and drug product impurities, now what? [J].MOJ Toxicol, 2017, 3(1): 9
[2] LI M, WANG X, CHEN B, et al. Use of liquid chromatography/tandem mass spectrometric molecular fingerprinting for the rapid structural identification of pharmaceutical impurities [J].Rapid Commun Mass Spectrom, 2009, 23(22):3533
[3] LI M, LIN MX, RUSTUM AM, et al. Application of LC-MSn in conjunction with mechanism-based stress studies in the elucidation of drug impurity structure: rapid identification of a process impurity in betamethasone 17-valerate drug [J].J Pharm Biomed Anal, 2008, 48(5): 1451
[4] KHUSHBOO SB. Antidepressants: mechanism of action, toxicity and possible amelioration [J].J Appl Biotechnol Bioeng, 2017, 3(5): 437
[5] MUELLER TI, LEON AC, KELLER MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up [J].Am J Psychiatry, 1999, 156(7): 1000
[6] BERMAN ME, MCCLOSKEY MS, FANNING JR, et al. Serotonin augmentation reduces response to attack in aggressive individuals [J].J Pharm Biomed Anal, 2008, 48(5): 1451
[7] KOWALSKA M, NOWACZYK J, FIJALKOWSKI L, et al. Paroxetine-overview of the molecular mechanisms of action [J].Int J Mol Sci, 2021, 22(4): 1662
[8] SYNTHON BV. 4-Phenylpiperidine Compounds for Treating Depression: US, 5874447 [P]. 1999-02-23
[9] TEVA PHARMACEUTICAL INDUSTRIES LTD. Stable Pharmaceutical Formulation of Paroxetine Hydrochloride and a Process for Preparation There of: US, 2003158230 [P]. 2003-08-21
[10] ENDO PHARMACEUTICALS INC. Process for Manufacturing Paroxetine Solid Dispersions: US, 5955475 [P]. 1999-01-13
[11] ENDO PHARMACEUTICALS INC. Aqueous Process for Manufacturing Paroxetine Solid Dispersions: US, 6168805 [P]. 2001-09-21
[12] ASAHI GLASS CO LTD. Method of Producing Amorphous Paroxetine Hydrochloride: EP, 0810224 [P]. 1997-12-03
[13] LIN JS, LIN ZH, LI D, et al. “Ghost peak” of clofazimine: a solution degradation product of clofazimine via nucleophilic substitution by nitrite leaching from certain glass HPLC vials [J].J Pharm Biomed Anal, 2018, 150(1): 183
[14] LIN JS, HUANG TP, FENG MX, et al. Solution degradant of mirabegron extended release tablets resulting from a Strecker-like reaction between mirabegron, minute amounts of hydrogen cyanide in acetonitrile, and formaldehyde in PEG during sample preparation [J].J Pharm Biomed Anal, 2019, 168(1): 181
[15] LIN JS, LIU XF, WANG J, et al. An artifactual solution degradant of pregabalin due to adduct formation with acetonitrile catalyzed by alkaline impurities during HPLC sample preparation [J].J Pharm Biomed Anal, 2019, 175(1): 112788
[16] LIN JS, CHEN FF, BAO CH, et al. Investigation of an artificial solution degradant of linagliptin: an undesired linagliptin urea derivative generates in sample preparation of linagliptin tablet treated by sonication in acetonitrile containing diluent [J].J Pharm Biomed Anal, 2022, 210(1): 114540
[17] TIAN Y, LIN JS, CHEN FF, et al. Structure elucidation and formation mechanistic study of a methylene-bridged pregabalin dimeric degradant in pregabalin extended-release tablets [J].Int J Pharmaceut, 2020, 575(1): 118910
[18] 方玉玲, 林金生, 朱文泉, 等. LC-PDA-QTOF-MS 联用法研究氯沙坦钾的未知工艺杂质 [J].药物分析杂志, 2017, 37(12): 2224
FANG YL, LIN JS, ZHU WQ, et al. Investigation study of process impurity in losartan potassium by LC-PDA-QTOF-MS [J].Chin J Pharm Ana, 2017, 37(12): 2224
[19] WANG SL, LIN JS, LI D, et al. Study of the isomeric Maillard degradants, glycosylamine and Amadori rearrangement products, and their differentiation via MS2 fingerprinting from collision-induced decomposition of protonated ions [J].Rapid Commun Mass Spectrom, 2021, 35(9): e9062
[20] KOCHETKOV NK, BUDOVSKII EI. Chapter 8, Hydrolysis of N-glycosidic bonds in nucleosides, nucleotides, and their derivatives, organic chemistry of nucleic acids [M].Springer, Boston, MA., 1972, 425
[21] 郑妍, 尤勇, 梁晓琴. 8-氧-2’-去氧鸟嘌呤核苷水解机理的理论研究 [J].原子与分子物理学报, 2014, 31(3): 355
ZHENG Y, YOU Y, LIANG XQ. Theoretic study on hydrolysis mechanism of 8-oxo-2’-deoxyguanosine [J].J Atomic Mol Phys, 2014,31(3):355
